The stock of Catalyst Biosciences, Inc. (CBIO) shows a multiple bottoms pattern with $9.96 target or 4.00 % below today’s $10.38 share price. The 6 months chart pattern indicates high risk for the $123.97M company. It was reported on Dec, 7 by Finviz.com. If the $9.96 price target is reached, the company will be worth $4.96 million less.
Multiple bottoms are very good trading chart patterns. These patterns have a low break even failure rate and decent average rise in a bull market, giving them a solid performance rank. Back-tests of such patterns show that the break even failure rate is 4%, the average rise: 37%, the throwback rate: 64% and the percentage of stocks meeting their price targets: 64%.
The stock increased 1.76% or $0.18 during the last trading session, reaching $10.38. About 105,195 shares traded. Catalyst Biosciences, Inc. (NASDAQ:CBIO) has risen 166.85% since December 7, 2017 and is uptrending. It has outperformed by 151.23% the S&P500.
Analysts await Catalyst Biosciences, Inc. (NASDAQ:CBIO) to report earnings on March, 7. They expect $-0.59 EPS, up 38.54 % or $0.37 from last year’s $-0.96 per share. After $-0.64 actual EPS reported by Catalyst Biosciences, Inc. for the previous quarter, Wall Street now forecasts -7.81 % EPS growth.
More notable recent Catalyst Biosciences, Inc. (NASDAQ:CBIO) news were published by: Globenewswire.com which released: “Catalyst Biosciences Announces Pricing of $18 Million Underwritten Public Offering – GlobeNewswire” on April 07, 2017, also Benzinga.com with their article: “Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings (Nov. 25-Dec. 1) – Benzinga” published on November 25, 2018, Globenewswire.com published: “Catalyst Biosciences Announces Appointment of Grant Blouse, Ph.D., as Vice President of Translational Research – GlobeNewswire” on July 10, 2018. More interesting news about Catalyst Biosciences, Inc. (NASDAQ:CBIO) were released by: Benzinga.com and their article: “Catalyst Biosciences (NASDAQ:CBIO) Shares Volatile On Positive Late-Stage Hemophilia Trial Results – Benzinga” published on July 18, 2018 as well as Globenewswire.com‘s news article titled: “Catalyst Biosciences Announces the Calling of Remaining Warrants and Conversion of Remaining Series A Preferred Shares Issued April 12, 2017 – GlobeNewswire” with publication date: March 05, 2018.
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. The company has market cap of $123.97 million. The Company’s product pipeline includes marzeptacog alfa, a Factor VIIa variant that completed a Phase I clinical trials evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and coagulation activity in severe hemophilia A and B patients with inhibitors. It currently has negative earnings. The firm also develops CB 2679d/ISU304, a Factor IX drug, which has completed preclinical studies for the prophylactic treatment of individuals with hemophilia B; and CB 2782, a pre-clinical anti-C3 protease program for the treatment of dry age-related macular degeneration.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.